Literature DB >> 9568640

Thymosin beta15 expression in tumor cell lines with varying metastatic potential.

L Bao1, M Loda, B R Zetter.   

Abstract

We previously isolated thymosin beta15 from highly metastatic Dunning rat prostatic carcinoma cells. Immunohistochemical study of human prostate cancer specimens revealed a general correlation between Gleason grade and thymosin beta15 expression, with high-grade (more malignant) tumors showing increased staining compared to low-grade tumors. To determine whether thymosin beta15 may be differentially expressed in cancer cells with different metastatic potential other than in the prostatic carcinoma cells, we examined thymosin beta15 mRNA levels in tumor cell lines from different species. We also examined thymosin beta15 protein levels in human breast cancer samples. Thymosin beta15 was upregulated in the highly metastatic mouse lung and human breast cancer cell lines in comparison to the nonmetastatic counterparts. Immunohistochemical staining showed the evidence of upregulation of thymosin beta15 in malignant human breast carcinomas as compared to benign breast tumors. The expression of thymosin beta15 was correlated with the metastatic potential of the mouse lung carcinoma and human breast carcinoma cells in addition to the prostatic carcinomas. Thymosin beta15 may be a useful marker to predict metastatic potential of certain human cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568640     DOI: 10.1023/a:1006540824969

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  24 in total

Review 1.  The cellular basis of site-specific tumor metastasis.

Authors:  B R Zetter
Journal:  N Engl J Med       Date:  1990-03-01       Impact factor: 91.245

2.  Motility of rat ascites hepatoma cells, with reference to malignant characteristics in cancer metastasis.

Authors:  S Hosaka; M Suzuki; M Goto; H Sato
Journal:  Gan       Date:  1978-04

3.  Fourier analysis of cell motility: correlation of motility with metastatic potential.

Authors:  A W Partin; J S Schoeniger; J L Mohler; D S Coffey
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Capping protein levels influence actin assembly and cell motility in dictyostelium.

Authors:  C Hug; P Y Jay; I Reddy; J G McNally; P C Bridgman; E L Elson; J A Cooper
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

5.  Thymosin-beta 4 gene. Preliminary characterization and expression in tissues, thymic cells, and lymphocytes.

Authors:  J Gómez-Márquez; M Dosil; F Segade; X R Bustelo; J G Pichel; F Dominguez; M Freire
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

6.  Developmental expression of mRNAs encoding thymosins beta 4 and beta 10 in rat brain and other tissues.

Authors:  S C Lin; M Morrison-Bogorad
Journal:  J Mol Neurosci       Date:  1990       Impact factor: 3.444

7.  Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities.

Authors:  P Brodt
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

8.  In vitro motility of cells from human epidermoid carcinomas. A study by phase-contrast and reflection-contrast cinematography.

Authors:  G Haemmerli; P Sträuli
Journal:  Int J Cancer       Date:  1981-05-15       Impact factor: 7.396

9.  Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.

Authors:  J L Mohler; A W Partin; J T Isaacs; D S Coffey
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

10.  Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes.

Authors:  L Cassimeris; D Safer; V T Nachmias; S H Zigmond
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

View more
  7 in total

1.  Differential expression of RAB5A in human lung adenocarcinoma cells with different metastasis potential.

Authors:  L Yu; F Hui-chen; Y Chen; R Zou; S Yan; L Chun-xiang; W Wu-ru; P Li
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

2.  Localization of thymosin beta10 in breast cancer cells: relationship to actin cytoskeletal remodeling and cell motility.

Authors:  Aase Elisabeth Maelan; Trine Kring Rasmussen; Lars-Inge Larsson
Journal:  Histochem Cell Biol       Date:  2006-06-20       Impact factor: 4.304

3.  A thymosin beta15-like peptide promotes intersegmental myotome extension in the chicken embryo.

Authors:  Verena Chankiewitz; Gabriela Morosan-Puopolo; Faisal Yusuf; Stefan Rudloff; Felicitas Pröls; Veronika Kleff; Dietrich Kurt Hofmann; Beate Brand-Saberi
Journal:  Histochem Cell Biol       Date:  2013-10-23       Impact factor: 4.304

Review 4.  Roles of thymosins in cancers and other organ systems.

Authors:  Changyi Chen; Min Li; Hui Yang; Hong Chai; William Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

5.  Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells.

Authors:  Tokushige Kobayashi; Futoshi Okada; Nobuyuki Fujii; Naoko Tomita; Satoru Ito; Hiroshi Tazawa; Tetsuya Aoyama; Sung Ki Choi; Toshiyuki Shibata; Hisakazu Fujita; Masuo Hosokawa
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

6.  Gene profiling of cottontail rabbit papillomavirus-induced carcinomas identifies upregulated genes directly Involved in stroma invasion as shown by small interfering RNA-mediated gene silencing.

Authors:  Evamaria Huber; Daniela Vlasny; Sonja Jeckel; Frank Stubenrauch; Thomas Iftner
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.

Authors:  Xiao Wang; Stefan Björklund; Agata M Wasik; Alf Grandien; Patrik Andersson; Eva Kimby; Karin Dahlman-Wright; Chunyan Zhao; Birger Christensson; Birgitta Sander
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.